Axe de Recherche sur les Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU De Québec-Université Laval, Québec, QC, Canada.
Division de Rhumatologie, Département de Médecine, Faculté de Médecine, Université Laval, Québec, QC, Canada.
Front Immunol. 2018 Oct 15;9:2269. doi: 10.3389/fimmu.2018.02269. eCollection 2018.
β1 integrins are critical for T cell migration, survival and costimulation. The integrin α2β1, which is a receptor for collagen, also named VLA-2, is a major costimulatory pathway of effector T cells and has been implicated in arthritis pathogenesis. Herein, we have examined its ability to promote methotrexate (MTX) resistance by enhancing effector T cells survival. Our results show that attachment of anti-CD3-activated human polarized Th17 cells to collagen but not to fibronectin or laminin led to a significant reduction of MTX-induced apoptosis. The anti-CD3+collagen-rescued cells still produce significant amounts of IL-17 and IFNγ upon their reactivation indicating that their inflammatory nature is preserved. Mechanistically, we found that the prosurvival role of anti-CD3+collagen involves activation of the MTX transporter ABCC1 (ATP Binding Cassette subfamily C Member 1). Finally, the protective effect of collagen/α2β1 integrin on MTX-induced apoptosis also occurs in memory CD4 T cells isolated from rheumatoid arthritis (RA) patients suggesting its clinical relevance. Together these results show that α2β1 integrin promotes MTX resistance of effector T cells, and suggest that it could contribute to the development of MTX resistance that is seen in RA.
β1 整合素对于 T 细胞的迁移、存活和共刺激至关重要。整合素 α2β1 是胶原蛋白的受体,也称为 VLA-2,是效应 T 细胞的主要共刺激途径,与关节炎发病机制有关。在此,我们研究了其通过增强效应 T 细胞的存活来促进甲氨蝶呤(MTX)耐药性的能力。我们的结果表明,抗 CD3 激活的人极化 Th17 细胞与胶原蛋白而非纤连蛋白或层粘连蛋白的附着导致 MTX 诱导的细胞凋亡显著减少。抗 CD3+胶原挽救的细胞在重新激活时仍产生大量的 IL-17 和 IFNγ,表明其炎症性质得以保留。从机制上讲,我们发现抗 CD3+胶原的促生存作用涉及 MTX 转运蛋白 ABCC1(ATP 结合盒亚家族 C 成员 1)的激活。最后,胶原/α2β1 整合素对 MTX 诱导的凋亡的保护作用也发生在从类风湿关节炎(RA)患者中分离的记忆 CD4 T 细胞中,提示其具有临床相关性。这些结果表明,α2β1 整合素促进效应 T 细胞对 MTX 的耐药性,并表明其可能导致 RA 中观察到的 MTX 耐药性的发展。